Open AccessQuality of Life during Treatment with Lenvatinib for Thyroid Cancer: The Patients’ Perspective beyond the Medical Evaluation
Author(s) -
Alice Nervo,
Alberto Ragni,
Marco Piovesan,
Valentina Marica,
Enrica Migliore,
Marco Gallo,
Emanuela Arvat
Publication year - 2020
Publication title -
european thyroid journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.23
H-Index - 10
eISSN - 2235-0802
pISSN - 2235-0640
DOI - 10.1159/000508186
Subject(s) - medicine , quality of life (healthcare) , common terminology criteria for adverse events , adverse effect , visual analogue scale , lenvatinib , clinical trial , population , refractory (planetary science) , thyroid cancer , physical therapy , cancer , physics , nursing , environmental health , astrobiology
Lenvatinib (LEN) has shown great efficacy but important toxicity in patients with advanced radioactive iodine-refractory (RAI-R) thyroid cancer (TC); a focused evaluation of its impact on patients' quality of life (QoL) is still lacking. Our prospective study investigated the impact of this drug on QoL in a group of RAI-R TC patients treated at our centre.